October 29, 2025

Can SGLT-2 Inhibitors Shield Against Autoimmune Disease?

Researchers found sodium-glucose cotransporter-2 inhibitors lowered autoimmune rheumatic disease risk by 11% in adults with type 2 diabetes.

Conexiant

October 29, 2025

H-1B Visa Changes: Who Pays the Price?

New fee structure could hit hardest where physicians are needed most.

Conexiant

October 24, 2025

A New Approach to Lowering Cardiovascular Risk?

Researchers evaluated obicetrapib’s effects on lipid levels and cardiovascular outcomes.

Conexiant

October 20, 2025

Obinutuzumab Wins FDA Nod for Lupus Nephritis

Roche's anti-CD20 antibody improved renal response and allowed for lower corticosteroid use in the phase III REGENCY trial, offering a twice-yearly maintenance option after initial dosing.

Conexiant

October 10, 2025

Benign MS Associated With Weight, IM, and Fish Intake

Obesity, infection, and diet history evaluated in long-term benign multiple sclerosis.

Conexiant

August 27, 2025

FDA Approves LP.8.1 COVID-19 Vaccines

LP.8.1-targeted COVID-19 vaccines for adults 65 and older and higher-risk patients were approved by the US Food and Drug Administration.

Conexiant

September 20, 2024

Lupus, IBD Share Microbiome Features, Study Shows

Microbiome analysis reveals SLE and IBD share up to 33 common short-chain fatty acid-producing enzymes, suggesting potential shared microbial mechanisms in these distinct autoimmune diseases.

Conexiant

April 29, 2024

A Look Ahead at Rheumatology in 2024

A rheumatologist reflected on rheumatology developments in 2023 and looked ahead to the developments and challenges the field may face in 2024.

Conexiant

April 30, 2024

Potential New Lyme Disease Therapy Advances to Human Safety Trials

The novel antibiotic therapy hygromycin A has advanced to human safety trials to determine its potential as a future treatment for Lyme disease.

Conexiant